Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Wedbush raised their Q3 2025 earnings per share estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, July 1st. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $1.35 for the quarter, up from their prior estimate of ($0.41). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.96) EPS and FY2027 earnings at $0.20 EPS.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.54) earnings per share.
View Our Latest Report on APLS
Apellis Pharmaceuticals Stock Up 0.9%
NASDAQ APLS opened at $17.99 on Friday. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. The stock has a market capitalization of $2.26 billion, a PE ratio of -10.05 and a beta of 0.67. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $42.47. The business’s 50-day moving average is $18.15 and its 200 day moving average is $23.52.
Insider Buying and Selling at Apellis Pharmaceuticals
In related news, General Counsel David O. Watson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the sale, the general counsel owned 133,730 shares of the company’s stock, valued at $2,510,112.10. This trade represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On Apellis Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC grew its position in Apellis Pharmaceuticals by 10.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company’s stock worth $390,011,000 after purchasing an additional 1,111,111 shares during the period. Vanguard Group Inc. grew its position in shares of Apellis Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company’s stock valued at $221,551,000 after acquiring an additional 84,331 shares during the period. AQR Capital Management LLC grew its position in shares of Apellis Pharmaceuticals by 119.6% during the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company’s stock valued at $89,173,000 after acquiring an additional 2,220,977 shares during the period. Geode Capital Management LLC grew its position in shares of Apellis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock valued at $58,699,000 after acquiring an additional 28,426 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Apellis Pharmaceuticals by 1.8% during the 4th quarter. Deutsche Bank AG now owns 1,778,377 shares of the company’s stock valued at $56,748,000 after acquiring an additional 30,867 shares during the period. Institutional investors own 96.29% of the company’s stock.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Recommended Stories
- Five stocks we like better than Apellis Pharmaceuticals
- What is the Hang Seng index?
- 3 Defense Leaders Set to Gain From Rising Military Spend
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why the Schwab Dividend ETF Rallied—and Can It Keep Climbing?
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 06/30 – 07/04
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.